Merck touts positive PhIII results for 21-valent pneumococcal vaccine candidate
Merck touted positive topline results on Thursday suggesting its experimental 21-valent pneumococcal conjugate vaccine candidate bested Pfizer’s 20-valent shot in a Phase III trial.
The New Jersey pharma giant’s V116 showed “statistically significant immune responses compared to PCV20” in serotypes common to both shots in a Phase III trial dubbed STRIDE-3 that enrolled 2,600 vaccine-naïve adults, Merck announced. Participants were assessed 30 days after being vaccinated.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.